Marathon Looking To Go The Distance In DMD
The biotech submitted an NDA to FDA for its DMD drug in hopes of succeeding where other companies have failed.
You may also be interested in...
ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
Even though investors viewed the FDA's willingness to give Sarepta another chance to provide more data as a positive step, most analysts said it was simply delaying the inevitable of rejecting the firm's Duchenne muscular dystrophy drug eteplirsen. Others have cautioned the FDA may be setting a new standard for approving rare disease drugs, in which other companies may demand similar attention.